Stefanie Zschäbitz, Head of Translational Uro-Oncology at Heidelberg University Hospital, shared on LinkedIn:
“Day 2 at IUCS26 in Guildford 🇬🇧 – key take-home messages!
Diagnostics meet therapeutics
- Sumanta Pal: Better molecular and imaging diagnostics are improving our understanding of RCC biology, new and promising assets at the horizon .
- Neeraj Agarwal: Comprehensive molecular testing is becoming increasingly important for treatment selection in prostate cancer.
- Petros Grivas: Bladder cancer biomarkers are moving beyond risk stratification towards guiding treatment decisions.
Uncommon histologies
- Vincenza Conteduca: Prostate cancer variants highlight the importance of re-biopsy for decision making
- Vadim Koshkin: Rare bladder and renal cancers require biology-driven, multidisciplinary care and clinical trials where possible.
- Daniele Raggi: In testicular cancer, individualised treatment is key to balance efficacy and long-term toxicity.
Patients at risk
- Vanita Noronha: Frailty and functional reserve matter more than chronological age when planning treatment.
- Xue-Yan Jiang (Xj): Early identification of patients at risk for immune-related adverse events supports safer immunotherapy.
- Aruni Ghose: Digital innovations should reduce – not widen – inequalities in cancer care.
Next clinical case quiz with Dra. María Natalia Gandur Quiroga, Maria Barbu and Akash Maniam.
Two fantastic days of science, discussion and international exchange.
Thank you to the whole IUCS26 community! Thank you to Giuseppe Banna, Ravindran Kanesvaran and Akash Maniam for this excellent meeting.“
Other articles about IUCS on OncoDaily.
